Human Genome Sciences, Inc. v. Eli Lilly and Co.
United Kingdom Supreme Court
[2011] UKSC 51 (2011)

- Written by Rich Walter, JD
Facts
Human Genome Sciences, Inc. (HGS) (defendant) identified a novel human protein as belonging to a superfamily of proteins known to share most, but not all, of the same chemical properties. HGS invented a method for isolating the new protein so that it could be applied to the same industrial uses for which the pharmaceuticals industry found superfamily proteins to be especially helpful. HGS patented its invention in accordance with the European Patent Convention (EPC), to which the United Kingdom (UK) was signatory. Eli Lilly and Company (Lilly) (plaintiff) opposed the patent and commenced revocation proceedings at the European Patent Office (EPO) and in UK courts. The EPO initially revoked the patent but was reversed by an EPO appeals board. However, a UK trial court revoked the patent’s validity within the UK. After an intermediate appellate court upheld the trial court’s action, HGS appealed to the UK Supreme Court.
Rule of Law
Issue
Holding and Reasoning (Neuberger, J.)
What to do next…
Here's why 832,000 law students have relied on our case briefs:
- Written by law professors and practitioners, not other law students. 46,500 briefs, keyed to 994 casebooks. Top-notch customer support.
- The right amount of information, includes the facts, issues, rule of law, holding and reasoning, and any concurrences and dissents.
- Access in your classes, works on your mobile and tablet. Massive library of related video lessons and high quality multiple-choice questions.
- Easy to use, uniform format for every case brief. Written in plain English, not in legalese. Our briefs summarize and simplify; they don’t just repeat the court’s language.